The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

AstraZeneca (GB:AZN) has released an update. Michel Demaré, the Non-Executive Chair of AstraZeneca, recently purchased 2,000 ordinary shares of ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s CEO, Pascal Soriot, has made a substantial investment in the company by ...

Medications used to treat diabetes and obesity are the hottest commodities in healthcare right now. Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have all become ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

At Stock Options Channel, our YieldBoost formula has looked up and down the AZN options chain for the new July 2025 contracts and identified one put and one call contract of particular interest.

Altria Group is "undervalued," Cramer says. On Oct. 31, the company reported third-quarter adjusted earnings per share of ...

Let's dig into the situation at AstraZeneca, and explore whether this is a good opportunity to buy the stock, as the company sets its sights on healthcare's next big renaissance. AstraZeneca has ...

(Reuters) -Drugmaker AstraZeneca (NASDAQ:AZN) lifted its annual sales and profit forecast for the second time this year on ...